Oppenheimer Starts Cleveland BioLabs (CBLI) at Outperform
Tweet Send to a FriendGet Alerts CBLI Hot Sheet
Price: $1.63 +4.49%
Rating Summary:
6 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
6 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade CBLI Now!
Oppenheimer initiates coverage on Cleveland BioLabs (NASDAQ: CBLI) with a Outperform. PT $3.00.
The firm comments, "Cleveland BioLabs is a development stage biotechnology company pursuing a broad pipeline of assets. The company's leading drug is Entolimod, which modulates apoptosis (natural cell death). This mechanism has a range of potential applications, including protecting healthy cells after injury such as radiation or oxygen deprivation, as well as a direct anti-tumor agent. Entolimod's most advanced indication is in biodefense as a therapeutic protectant following radiation exposure. The company is commencing pivotal studies, and we anticipate a BLA filing in 4Q14. Entolimod appears to be well differentiated in the biodefense application, with a significant barrier to entry for competitors."
For an analyst ratings summary and ratings history on Cleveland BioLabs click here. For more ratings news on Cleveland BioLabs click here.
Shares of Cleveland BioLabs closed at $1.40 yesterday, with a 52 week range of $1.15-$4.06.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm comments, "Cleveland BioLabs is a development stage biotechnology company pursuing a broad pipeline of assets. The company's leading drug is Entolimod, which modulates apoptosis (natural cell death). This mechanism has a range of potential applications, including protecting healthy cells after injury such as radiation or oxygen deprivation, as well as a direct anti-tumor agent. Entolimod's most advanced indication is in biodefense as a therapeutic protectant following radiation exposure. The company is commencing pivotal studies, and we anticipate a BLA filing in 4Q14. Entolimod appears to be well differentiated in the biodefense application, with a significant barrier to entry for competitors."
For an analyst ratings summary and ratings history on Cleveland BioLabs click here. For more ratings news on Cleveland BioLabs click here.
Shares of Cleveland BioLabs closed at $1.40 yesterday, with a 52 week range of $1.15-$4.06.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- BTIG Starts Ambac Financial (AMBC) at Buy, Interesting Play with 'Optionality'
- Barclays Starts Leap Wireless (LEAP) at Underweight
- Barclays Starts Crown Castle (CCI) at Equalweight
Create E-mail Alert Related Categories
Hot New Coverage, New Coverage
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
